Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Dissecting the Multiplicity of Immune Effects of Immunosuppressive Drugs to Better Predict the Risk of de novo Malignancies in Solid Organ Transplant Patients.

Cangemi M, Montico B, Faè DA, Steffan A, Dolcetti R.

Front Oncol. 2019 Mar 27;9:160. doi: 10.3389/fonc.2019.00160. eCollection 2019. Review.

2.

Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIV-infected patient.

Caccuri F, Muraro E, Gloghini A, Turriziani O, Riminucci M, Giagulli C, Mastorci K, Fae' DA, Fiorentini S, Caruso A, Carbone A, Dolcetti R.

Hematol Oncol. 2019 Apr;37(2):176-184. doi: 10.1002/hon.2562. Epub 2018 Nov 6.

PMID:
30261551
3.

Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer.

Muraro E, Furlan C, Avanzo M, Martorelli D, Comaro E, Rizzo A, Fae' DA, Berretta M, Militello L, Del Conte A, Spazzapan S, Dolcetti R, Trovo' M.

Front Immunol. 2017 Nov 6;8:1476. doi: 10.3389/fimmu.2017.01476. eCollection 2017.

4.

A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors.

Turrini R, Merlo A, Martorelli D, Faè DA, Sommaggio R, Montagner IM, Barbieri V, Marin O, Zanovello P, Dolcetti R, Rosato A.

Oncoimmunology. 2017 Mar 16;6(4):e1304338. doi: 10.1080/2162402X.2017.1304338. eCollection 2017.

5.

Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma.

Mastorci K, Montico B, Faè DA, Sigalotti L, Ponzoni M, Inghirami G, Dolcetti R, Dal Col J.

Oncotarget. 2016 Jul 5;7(27):41913-41928. doi: 10.18632/oncotarget.9630.

6.

Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy.

Faè DA, Martorelli D, Mastorci K, Muraro E, Dal Col J, Franchin G, Barzan L, Comaro E, Vaccher E, Rosato A, Dolcetti R.

Cancer Immunol Res. 2016 May;4(5):431-40. doi: 10.1158/2326-6066.CIR-15-0108. Epub 2016 Mar 23.

7.

A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting.

Martorelli D, Muraro E, Mastorci K, Dal Col J, Faè DA, Furlan C, Giagulli C, Caccuri F, Rusnati M, Fiorentini S, Carbone A, Caruso A, Dolcetti R.

Int J Cancer. 2015 Sep 15;137(6):1374-85. doi: 10.1002/ijc.29494. Epub 2015 Mar 9.

8.

Detection of HIV-1 matrix protein p17 quasispecies variants in plasma of chronic HIV-1-infected patients by ultra-deep pyrosequencing.

Giombini E, Dolcetti R, Caccuri F, Selleri M, Rozera G, Abbate I, Bartolini B, Martorelli D, Faè DA, Fiorentini S, Giagulli C, Capobianchi MR, Caruso A.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):332-9. doi: 10.1097/QAI.0000000000000164.

PMID:
24732873
9.

Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.

Martorelli D, Muraro E, Merlo A, Turrini R, Faè DA, Rosato A, Dolcetti R.

Clin Dev Immunol. 2012;2012:931952. doi: 10.1155/2012/931952. Epub 2012 Jan 29. Review.

10.

Retinoic acid/alpha-interferon combination inhibits growth and promotes apoptosis in mantle cell lymphoma through Akt-dependent modulation of critical targets.

Dal Col J, Mastorci K, Faè DA, Muraro E, Martorelli D, Inghirami G, Dolcetti R.

Cancer Res. 2012 Apr 1;72(7):1825-35. doi: 10.1158/0008-5472.CAN-11-2505. Epub 2012 Feb 6.

Supplemental Content

Support Center